Generate QR code
Open Access
Subscription Access
Epigenetic stem cell index as a prognostic marker in breast cancer
https://doi.org/10.25557/2073-7998.2025.06.59-61
Abstract
Breast tumor contains various cell types, including cancer stem cells, a small proportion of which survive chemotherapy and lead to recurrence or metastasis. With this in mind, the aim of the study is to evaluate the prognostic potential of the stem cell epigenetic index. 19 luminal B breast cancer samples were used for statistical analysis and deconvolution. Comparison of samples with and without metastasis showed a statistically significant (p < 0.05) predominance of the index in samples without metastasis, and survival curve analysis showed a significant increase (p < 0.05) in metastatic-free survival associated with high index. The results obtained allow using the epigenetic index of stem cells as a prognostic marker for metastasis-free survival.
Supporting agencies: The work was carried out under the state assignment of the Ministry of Science and Higher Education of Russia for the Research Centre for Medical Genetics
About the Authors
A. I. Kalinkin
Research Centre for Medical Genetics
Russian Federation
Russian Federation
1, Moskvorechye st., Moscow, 115522
V. O. Sigin
Research Centre for Medical Genetics
Russian Federation
Russian Federation
1, Moskvorechye st., Moscow, 115522
A. F. Nikolaeva
Research Centre for Medical Genetics
Russian Federation
Russian Federation
1, Moskvorechye st., Moscow, 115522
M. K. Ibragimova
Cancer Research Institute Tomsk National Research Medical Center of the Russian Academy of Sciences
Russian Federation
Russian Federation
5, Kooperativny st., Tomsk, 634009
M. M. Tsyganov
Cancer Research Institute Tomsk National Research Medical Center of the Russian Academy of Sciences
Russian Federation
Russian Federation
5, Kooperativny st., Tomsk, 634009
A. N. Demko
Ryazan State Medical University
Russian Federation
Russian Federation
9, Vysokovol’tnaya st., Ryazan, 390026
M. V. Shomova
Regional Clinical Oncology Dispensary
Russian Federation
Russian Federation
11, Sportivnaya st., Ryazan, 390046
L. E. Silantyeva
Regional Clinical Oncology Dispensary
Russian Federation
Russian Federation
11, Sportivnaya st., Ryazan, 390046
I. I. Vinogradov
Ryazan State Medical University; Regional Clinical Oncology Dispensary
Russian Federation
Russian Federation
9, Vysokovol’tnaya st., Ryazan, 390026; 11, Sportivnaya st., Ryazan, 390046
N. V. Litvyakov
Cancer Research Institute Tomsk National Research Medical Center of the Russian Academy of Sciences
Russian Federation
Russian Federation
5, Kooperativny st., Tomsk, 634009
V. V. Strelnikov
Research Centre for Medical Genetics
Russian Federation
Russian Federation
1, Moskvorechye st., Moscow, 115522
References
1. Lüönd F., Tiede S., Christofori G. Breast cancer as an example of tumour heterogeneity and tumour cell plasticity during malignant progression. British journal of cancer. 2021;125(2):164-175.
2. Toh T. B., Lim J. J., Chow E. K. H. Epigenetics in cancer stem cells. Molecular cancer. 2017;16:1-20.
3. Sigin V.O., Kalinkin A.I., Kuznetsova E.B. et al. DNA methylation markers panel can improve prediction of response to neoadjuvant chemotherapy in luminal B breast cancer. Scientific Reports. 2020;10(1): 9239.
Review
For citations:
Kalinkin A.I., Sigin V.O., Nikolaeva A.F., Ibragimova M.K., Tsyganov M.M., Demko A.N., Shomova M.V., Silantyeva L.E., Vinogradov I.I., Litvyakov N.V., Strelnikov V.V. Epigenetic stem cell index as a prognostic marker in breast cancer. Medical Genetics. 2025;24(6):59-61. (In Russ.) https://doi.org/10.25557/2073-7998.2025.06.59-61
Views:
8
Email this article 